Nuvectis Pharma Inc.
NVCT | NASDAQ
$21.98
-$0.02 (-0.09%)
At close: Sep 21, 2026, 4:00 PM ET
$21.98
$0 (0.00%)
After-hours:
Sep 21, 2026, 4:10 PM ET
Fiscal Year Period Ending | FY 2025 Dec 30, 2025 | FY 2024 Dec 30, 2024 | FY 2023 Dec 30, 2023 | FY 2022 Dec 30, 2022 | FY 2021 Dec 30, 2021 | FY 2020 Dec 30, 2020 |
|---|---|---|---|---|---|---|
Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -27.57M | -19.85M | -22.9M | -19.23M | -12.89M | -10K |
Interest Income | 1.13M | 847K | 637K | 149K | 4K | n/a |
Pretax Income | -26.44M | -19M | -22.26M | -19.09M | -12.89M | -10K |
Net Income | -26.44M | -19M | -22.26M | -19.09M | -12.89M | -10K |
Selling & General & Admin | 9.42M | 6.93M | 7.52M | 6.01M | 3.35M | 10K |
Research & Development | 18.15M | 12.92M | 15.38M | 13.23M | 9.55M | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 27.57M | 19.85M | 22.9M | 19.23M | 12.89M | 10K |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 27.57M | 19.85M | 22.9M | 19.23M | 12.89M | 10K |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 21.81M | 17.11M | 15.56M | 12.66M | 12.72M | 12.72M |
Shares Outstanding (Diluted) | 21.81M | 17.11M | 15.56M | 12.66M | 12.72M | 12.72M |
EPS (Basic) | -1.32 | -1.11 | -1.43 | -1.51 | -1.09 | 0 |
EPS (Diluted) | -1.32 | -1.11 | -1.43 | -1.51 | -1.09 | 0 |
EBITDA | -26.44M | -19M | -22.26M | -19.09M | -12.89M | -10K |
EBIT | -26.44M | -19M | -22.26M | -19.09M | -12.89M | -10K |
Depreciation & Amortization | n/a | n/a | n/a | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove NVCT